Sophia Genetics, Strand Life Sciences Forge Strategic Partnership to Advance Precision Medicine
Written by Arushi Sharma
Sophia Genetics and Strand Life Sciences announce a strategic partnership to accelerate the adoption of precision medicine worldwide. This collaboration leverages Sophia Genetics' cloud-based software platform and Strand Life Sciences' expertise in bioinformatics and diagnostics.
Sophia Genetics, a leading cloud-native software company, has joined forces with Strand Life Sciences, a prominent player in bioinformatics and diagnostics, in a groundbreaking collaboration aimed at propelling the global adoption of precision medicine.
This strategic alliance will leverage cutting-edge genomics technologies, bioinformatics services, and diagnostics solutions to revolutionize patient care on a global scale.
Based in Bengaluru, Strand Life Sciences boasts a formidable track record in supporting a diverse global clientele with its innovative applications tailored to enhance the utilization of precision medicine. Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences, Bengaluru, expressed optimism about the partnership, affirming, “Our collaboration with Sophia Genetics will empower organizations to usher in the era of next-generation precision medicine, thereby significantly enhancing patient care outcomes.”
The collaboration between Sophia Genetics and Strand Life Sciences heralds an era of heightened capabilities in healthcare data analysis, facilitating data-driven decision-making processes worldwide. Sophia Genetics will extend its support through the Sophia DDM platform, while Strand will contribute its variant databases and unmatched expertise in bioinformatics solutions. Together, the two entities will embark on strategic endeavors, including test co-development initiatives, aimed at enhancing healthcare outcomes in India and beyond.
Jurgi Camblong, PhD., CEO and Co-founder of Sophia Genetics, underscored the significance of the partnership in addressing the critical need for expedited data processing and accurate results delivery in healthcare. “Healthcare organizations necessitate the ability to swiftly process data and obtain precise results, enabling prompt and efficacious treatments for cancers and rare diseases. This partnership is poised to fulfill that imperative,” Dr. Camblong remarked.
The collaborative efforts between Sophia Genetics and Strand Life Sciences represent a significant stride towards democratizing access to precision medicine, with profound implications for healthcare delivery worldwide. As the partners embark on this transformative journey, the fusion of advanced technologies and domain expertise promises to redefine the landscape of patient-centric care, ushering in a new era of medical innovation and improved health outcomes for all.